Catalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying Opportunity (CPRX)
koto_feja/E+ via Getty Images Company website Investment Thesis Rating Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Buy with 2-5 year target of $40 (3x upside) based on the discounted cash flow (“DCF”) valuation method. Steroids are used in 70% of patients with Duchenne’s muscular dystrophy, DMD, a debilitating neuromuscular disease, which is a 2 billion/year market and is…